Results 171 to 180 of about 10,552,439 (323)

The DNA/RNA autophagy protein SIDT2 as a novel neuropathological hallmark in Huntington disease

Brain Pathology, EarlyView.
SIDT2‐immunoreactive inclusions are observed in the striatum, cerebral cortex, and hypothalamus in HD cases with different Vonsattel grades, and the frequency of SIDT2‐immunoreactive inclusions is associated with longer CAG repeats in the huntingtin gene.
Sanaz Gabery, Sofia Bergh, Chrisovalantou Huridou, Rachel Y. Cheong, Barbara Baldo, Paul Günther Scheunemann, Marie‐Louisa Schoebel, Linda Holmquist Mengelbier, Elisabet Englund, Catriona McLean, Carsten Saft, Deniz Kirik, Maria Björkqvist, Glenda Halliday, Elisabeth Petrasch‐Parwez, Huu Phuc Nguyen, Jonasz Jeremiasz Weber, Åsa Petersén   +17 more
wiley   +1 more source

Cell-specific mechanisms drive connectivity across the time course of Huntington’s disease

Nature Communications
Hyperconnectivity in functional brain networks occurs decades before disease onset in Huntington’s disease. However, the biological mechanisms remain unknown. We investigate connectivity in Huntington’s disease using Morphometric INverse Divergence (MIND)
Carlos Estevez-Fraga, Isaac Sebenius, Justine Y. Hansen, Benjamin Hänisch, Paul Zeun, Rachael I. Scahill, Sarah Gregory, Eilanoir B. Johnson, Edward J. Wild, Lauren M. Byrne, Alexandra Durr, Bernhard Landwehrmeyer, Blair R. Leavitt, Bratislav Misic, Sofie Louise Valk, Geraint Rees, Sarah J. Tabrizi, Peter McColgan   +17 more
doaj   +1 more source

Priming with interleukin‐1α and chemical hypoxia modulates the mesenchymal stem cell secretome to dampen microglial inflammation and promote neuroprotection

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose We hypothesised that dual priming of human bone marrow‐derived human mesenchymal stem cells (hBMSCs) with interleukin‐1alpha (IL‐1α) and CoCl2 (a hypoxia mimetic) would modulate their therapeutic efficacy for hypoxic‐ischaemic conditions. Experimental Approach hBMSCs were primed individually or in combination.
Maryam Adenike Salaudeen, Stuart M. Allan, Emmanuel Pinteaux   +2 more
wiley   +1 more source

The role of protein arginine methyltransferases in sickle cell‐mediated neurovascular impairments in mice

British Journal of Pharmacology, EarlyView.
Background and Purpose Sickle cell disease (SCD) is a hereditary blood disorder caused by mutation of β‐globin. In SCD, haemoglobin polymerization causes red blood cells to assume a rigid sickle‐shape leading to neurovascular alterations, including development of vascular dementia – characterized by cognitive impairment and reduced cerebral perfusion ...
Julia Zaccarelli‐Magalhães, Mariana Sayuri Berto Udo, Drew James Smith, Julia Langman, Luiz Henrique Matuguma, Guilherme Nagamine Gomes, Peter Rodriguez, Ammar Husan, Quanguang Zhang, Christopher G. Kevil, Cristiane Teresinha Citadin, Hung Wen Lin   +11 more
wiley   +1 more source

Huntington’s Disease Clinical Trials Corner: June 2019 [PDF]

, 2019
In this edition of the Huntington’s Disease Clinical Trials Corner we expand on the HD-DBS and on the TRIHEP3 trials, and we list all currently registered and ongoing clinical trials in Huntington’s ...
Ferreira, JJ, Wild, EJ, Brogueira Rodrigues, F   +2 more
core  

Role of funders in embedding tests in conservation practice

Conservation Biology, EarlyView.
Abstract Effective conservation practice requires decisions based on reliable and relevant evidence, but significant gaps in the evidence base exist. Incorporating well‐designed tests of the effectiveness of interventions for biodiversity in conservation projects is one of the best ways to scale up the rate of evidence generation.
Rebecca K. Smith, Nancy Ockendon, Nida Al‐Fulaij, Alessandro Badalotti, Rachel Beattie, James Byrne, Sophia Cooke, Tiago de Zoeten, Winifred F. Frick, Stephan M. Funk, Douglas Gibbs, Lauren Gupta, Tatiana Hendrix, Becky Holmes, Nicola Johnstone, James Kinghorn, Simon Mickleburgh, Florence Miller, Matthew Muir, Jacob R. Owens, Danni Parks, Victoria Reilly‐Pinion, Hannah Reid, Kevin Seely, Julien Semelin, Taylor Shaw, Ruth D. Swetnam, Lisa Wheeler, William J. Sutherland   +28 more
wiley   +1 more source

Proteostasis of organelles in aging and disease

The FEBS Journal, EarlyView.
Cells rely on regulated proteostasis mechanisms to keep their internal compartments functioning properly. When these mechanisms fail, damaged proteins accumulate, disrupting organelles, such as the nucleus, mitochondria, endoplasmic reticulum, Golgi, and lysosomes, as well as membraneless organelles, such as stress granules, processing bodies, the ...
Yara Nabawi, Cansu Doğan, Dunja Petrović, Gülce Perçin, Seda Koyuncu, David Vilchez   +5 more
wiley   +1 more source

Iloperidone treatment mitigates the Juvenile Huntington's Disease phenotype possibly via Sigma‐1 Receptor Modulation

The FEBS Journal, EarlyView.
We investigated the potential of iloperidone as an activator of Sigma‐1 receptor (S1R) neuroprotective function in juvenile Huntington's disease (jHD). We tested iloperidone on cortical neurons differentiated from patient‐derived iPSCs, demonstrating that it acts as a S1R agonist, decreasing apoptosis, huntingtin aggregation, and oxidative stress ...
Ersilia Fornetti, Gaia Galluzzi, Mario Frezzini, Cécile Exertier, Vittorio Brufani, Gianni Colotti, Giancarlo Ruocco, Jessica Rosati, Angelo Luigi Vescovi, Daniele Narzi, Ilaria Genovese, Andrea Ilari   +11 more
wiley   +1 more source

Stimulating proteasomal degradation in human proteinopathies

The FEBS Journal, EarlyView.
The proteasome mediates the degradation of a wide range of proteins. Boosting proteasomal degradation may be beneficial in several disease contexts and can be achieved either by modulating proteasome activity or by improving substrate delivery. Proteasome activity can be enhanced by increasing proteasome abundance, inducing constitutive gate opening ...
Maria E. Gierisch, Enrica Barchi, Nico P. Dantuma   +2 more
wiley   +1 more source

PromOTing Quality of Life for Individuals with Huntington’s Disease [PDF]

, 2015
Objectives of Presentation: Describe the symptoms of Huntington’s disease and their impact on functional performance. Recognize the role of occupational therapy in improving quality of life for individuals with Huntington’s disease.
Koch, OTS, Mallory, Sadofsky, OTS, Sarah, Gentile, OTS, Lyndsay, McCabe, OTS, Elyse, Royal, OTS, Jessica   +4 more
core   +1 more source